1 Prediction of transporter-mediated drug-drug interactions

2 and phenotyping of hepatobiliary transporters involved in

3 the clearance of E7766, a novel macrocycle-bridged

4 dinucleotide

- 5 Rongrong Jiang^{*}, Andrew Hart¹, Laurette Burgess, Dae-Shik Kim, Weidong Lai², Vaishali Dixit^{*}
- 6 Drug Metabolism and Pharmacokinetics, Eisai Inc, Massachusetts, USA (R.J., V.D., G.L., A.H.)
- 7 Genetics Guided Dementia Discovery, Eisai Inc, Massachusetts, USA (L.B., DS.K.)
- 8 ¹Current Address: Wave Life Sciences, Massachusetts, USA
- 9 ²Current Address: Triplet Therapeutics, Massachusetts, USA
- 10 ^{*}*Co-corresponding authors*

11 **Running Title:** Transporter-mediated drug-drug interactions for E7766

12 **Co-corresponding authors**

- 13 Dr. Rongrong Jiang, Drug Metabolism and Pharmacokinetics, Eisai Inc, Cambridge
- 14 Massachusetts, USA. Tel: (857) 829-6063; E-mail: Rongrong_jiang@eisai.com
- 15 Dr. Vaishali Dixit, E-mail: dixitv77@gmail.com

16

17

- 18 Number of text pages: 25
- 19 Words in the Abstract: 243
- 20 Words in the Introduction: 591
- 21 Words in the Discussion: 1341
- 22 Number of references: 35
- 23 Number of Tables: 5
- 24 Number of Figures: 5
- 25 Number of Supplemental Tables: 4
- 26 Number of Supplemental Figures: 3

28 List of abbreviations

Ae fecal, amount excreted in feces; Ae biliary, amount excreted in bile; Ae renal, amount excreted in 29 30 urine; BCRP, breast cancer resistance protein; BSEP, bile salt export pump; CL_{biliary}, hepatobiliary excretory clearance; CL_{fecal}, fecal excretory clearance; CL_{int}, intrinsic clearance; 31 $CL_{tot,p}$, total plasma clearance; CL_{renal} , renal excretory clearance; K_m , Michaelis-Menten constant; 32 33 MDR, multidrug resistance; MRP, multidrug resistance-associated protein; NCEs, new chemical entities; NTCP, Na⁺/taurocholate cotransporting polypeptide; OAT, organic anion transporter; 34 OATP, organic anion transporting polypeptide; OCT, organic cation transporter; PBPK, 35 physiologically based pharmacokinetic; PK, pharmacokinetic; V_{max} , maximum transport velocity; 36 $V_{\rm SS}$, distribution volume at steady state. 37

39 Abstract

E7766 represents a novel class of macrocycle-bridged dinucleotides, and is under clinical 40 development for immuno-oncology. In this report, we identified mechanism of systemic 41 clearance E7766, investigated the hepatobiliary transporters involved in the disposition of E7766 42 and potential drug interactions of E7766 as a victim of organic anion transporting polypeptide 43 (OATP) inhibitors. In bile-duct cannulated (BDC) rats and dogs, E7766 was mainly excreted 44 45 unchanged in bile (>80%) and to a lesser extent in urine (<20%). Sandwich cultured human hepatocytes (SCHH), transfected cells and vesicles were used to phenotype the hepatobiliary 46 transporters involved in the clearance of E7766. SCHH data showed temperature-dependent 47 uptake of E7766, followed by active biliary secretion. In vitro transport assays using transfected 48 cells and membrane vesicles confirmed that E7766 was a substrate of OATP1B1, OATP1B3 and 49 multidrug resistance-associated protein 2 (MRP2). Phenotyping studies suggested predominant 50 51 contribution of OATP1B3 over OATP1B1 in the hepatic uptake of E7766. Studies in OATP1B1/1B3 humanized mice showed that plasma exposure of E7766 increased 4.5-fold when 52 coadministered with Rifampicin. Physiologically based pharmacokinetic (PBPK) models built 53 upon two independent bottom-up approaches predicted elevation of E7766 plasma exposure 54 when administered with Rifampicin, a clinical OATP inhibitor. In conclusion, we demonstrate 55 that OATP-mediated hepatic uptake is the major contributor to the clearance of E7766 and 56 inhibition of OATP1B may increase its systemic exposure. Predominant contribution of 57 OATP1B3 in the hepatic uptake of E7766 was observed, suggesting polymorphisms in 58 59 OATP1B1 would be unlikely to cause variability in the exposure of E7766.

61 Significance Statement

Understanding the clearance mechanisms of new chemical entities is critical to predicting human pharmacokinetics and drug interactions. A physiologically based pharmacokinetic model that incorporated parameters from mechanistic in vitro and in vivo experiments was used to predict pharmacokinetics and drug interactions of E7766, a novel dinucleotide drug. The findings highlighted here may shed a light on the pharmacokinetic profile and transporter-mediated drug interaction propensity of other dinucleotide drugs.

69 Introduction

70 Stimulator of interferon genes (STING) is an important innate immune sensor, and activation of STING plays a critical role in controlling cancer development by bridging the innate and 71 adaptive immunities (Corrales et al., 2016; Woo et al., 2014). Significant efforts have been made 72 by several pharmaceutical companies to develop potent agonists of the STING receptor 73 74 (Marloyle et al., 2019). We have recently reported the discovery of E7766 (Figure 1), a potent 75 STING agonist that belongs to a novel class of macrocycle-bridged dinucleotides (Endo et al., 76 2019). In nonclinical studies, E7766 has demonstrated potent antitumor activity by inducing a robust and effective innate and adaptive antitumoral immune response (Huang et al., 2019). 77 78 Macrocycle-bridged dinucleotides were generally characterized by moderate to high molecular weight (>400), low logP (<1) and pKa of 3-4. Macrocycle-bridged dinucleotides also have low 79 permeability, and as such fall in the Class 3B of the extended clearance classification system 80 81 (ECCS) (Varma et al., 2015), thus making them potential substrates for hepatic uptake and efflux 82 transporters. Many compounds in this series showed high clearance that was at or exceeded hepatic blood flow and had low volume of distribution. Additionally, the compounds were 83 metabolically stable in rodent and human hepatocytes and liver S9 fraction indicating that 84 metabolism was unlikely the primary clearance pathway. Identifying clearance mechanisms of 85 86 these novel class compounds in drug discovery is important to predict systemic and target tissue exposure, as well as to predict clinical drug-drug interaction (DDI). 87

The significant clinical implications of inhibiting hepatic uptake transporters such as OATP1B have highlighted the importance of assessing this potential liability for new chemical entities (NCEs) during drug discovery and development (Chen et al., 2018). The US Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) have also issued

DMD Fast Forward. Published on December 18, 2020 as DOI: 10.1124/dmd.120.000125 This article has not been copyedited and formatted. The final version may differ from this version.

Downloaded from dmd.aspetjournals.org at ASPET Journals on April 18, 2024

92 guidance for the in vitro and in vivo evaluation of the transporter-based DDI (EMA, 2012; FDA, 2017). Predicting DDI for substrates of OATP1B1 and OAPT1B3 has recently been described in 93 94 many reports (Duan et al., 2017; Yoshikado et al., 2018). Physiologically based pharmacokinetic (PBPK) modeling has been recognized to be a powerful tool for PK and DDI predictions of 95 substrates of hepatic uptake transporters as well as drug metabolizing enzymes (Jones et al., 96 97 2015; Wang et al., 2017). In addition to predicting DDI, PBPK can also be used in the mechanistic understanding of various rate-limiting and rate-determining processes in the 98 99 disposition of drugs.

100 E7766 was selected as a suitable model compound for investigating the clearance mechanisms and transporter-mediated DDI propensity of macrocycle-bridged dinucleotide-type STING 101 agonists. A series of nonclinical studies were planned and conducted to 1) assess the major 102 103 clearance mechanisms in the systemic clearance of E7766; 2) identify the transporters and 104 estimate their relative contributions to the hepatic clearance of E7766, and 3) use the in vitro transporter data and PBPK model framework to prospectively predict the clinical DDI of E7766 105 with OATP1B inhibitor. To best of our knowledge, this is the first report for the identification of 106 hepatobiliary transporters and PBPK modeling-based DDI prediction of therapeutically 107 108 important and structurally novel macrocycle-bridged dinucleotides. Our data underscores the 109 importance of OATP1B, especially OATP1B3, in determining the systemic hepatic clearance rate and hence the plasma exposure of E7766 and perhaps this class of compounds. Furthermore, 110 111 our results also show that clinically relevant DDIs leading to changes in plasma exposure can occur if E7766 is coadministered with OATP1B3 inhibitors. The predominant contribution of 112 113 OATP1B3 to the clearance of E7766 suggests that the plasma exposure to E7766 is less likely to 114 be subjected to inter-individual variability due to polymorphisms in OATP1B1.

DMD Fast Forward. Published on December 18, 2020 as DOI: 10.1124/dmd.120.000125 This article has not been copyedited and formatted. The final version may differ from this version.

116 Materials and Methods

117 Chemicals and reagents

E7766 and the internal standard (IS), ER-001229535 (Lot No. ER-001229535-NH4-011), were 118 synthesized at Eisai Inc. (Andover, MA). Bovine serum albumin solution was purchased from 119 American Tissue Culture Collection (ATCC; Manassas, VA). Estradiol-17β-glucuronide 120 $(E_2 17\beta G)$, Rifampicin, and Krebs-Henseleit buffer (KH buffer) were purchased from Sigma-121 Aldrich (St. Louis, MO). Porcine kidney LLC–PK1 (parentalcells were obtained from Discovery 122 Labware, Inc (now Corning Inc., Tewkbury, MA). HEK293-FT cells stably transfected with the 123 vector containing OATP1B1 cDNA or OATP1B3 cDNA, or empty vector were obtained from 124 Solvo Biotechnology (Zeged, Hungary). TransportoCellsTM transiently transfected with the 125 126 vector containing OATP2B1 cDNA or NTCP cDNA, or empty vector were purchased from 127 Corning (NY, USA). The cell culture related reagents were cell culture grade, and were purchased from Thermo Scientific, Inc. (Herndon, VA). All other reagents used in this study 128 129 were of either analytical or HPLC grade.

130 Transport studies of E7766 with hepatic Solute Carrier (SLC) transporters

TransportoCellsTM (Corning, NY, USA) transiently expressing OATP2B1 or NTCP and the 131 control cells (HEK293 cells transfected with empty vector), and HEK293FT cell line (Solvo 132 Biotechnology, Zeged, Hungary) stably expressing OATP1B1 (HEK293FT-OATP1B1) or 133 OATP1B3 (HEK293FT-OATP1B3) and the control cells (HEK293FT-control; HEK293FT cells 134 transfected with empty vector) were grown in a Dulbecoo's modified Eagle's medium fortified 135 with 10% fetal calf serum and 2 mmol/L sodium butyrate (for NTCP only) in a humidified 136 137 incubator at 37°C and 5% CO₂. Solvo HEK293-FT cells were harvested at 90% confluence and then seeded in poly-D-lysine-coated 24-well 24 h prior to transporter assay while Corning 138

139 TransportoCellsTM were thawed and seeded in poly-D-lysine-coated 96-well 24 h prior to transporter assay. Cellular transport assays were conducted as described previously (Jiang et al., 140 2015). Briefly, cells were washed twice and pre-incubated with 200 μ L of pre-warmed Krebs-141 Henseleit (KH) buffer. After pre-incubation, cells were incubated with 3 or 10 µmol/L of E7766 142 in presence or absence of 100 µmol/L of inhibitors (Rifamycin SV for OATP2B1, Troglitazone 143 for NTCP, and Rifampicin for OATP1B1 and OATP1B3). The transport reaction was terminated 144 by aspirating the buffer from the wells at designated time. After washing three times with 200 µL 145 of ice-cold KH buffer, the cells were lysed and the resulting cellular lysates were analyzed by 146 147 LC-MS/MS.

The time-dependent uptake of E7766 with OATP1B1 and OATP1B3 was evaluated to
confirm linear uptake condition range of uptake of E7766 (Supplemental Figure 2).
Concentration-dependent uptake of E7766 via OATP1B1 and OATP1B3 was examined with a
concentration range of 0.25-100 µmol/L under linear conditions at 5 minutes. All experiments
were run in triplicates.

153 Transport studies of E7766 with hepatic ABC transporters

154 TransportoCells[™] membrane vesicles (Corning, NY, USA) expressing MDR1, BCRP, BSEP, or 155 MRP2, and control vector vesicles (70 μ L) were pre-incubated with vesicle uptake buffer (47 156 mmol/L MOPs-Tris, 65 mmol/L KCl, 7 mmol/L MgCl₂, pH 7.4 for MDR1 and BCRP; 47 157 mmol/L MOPs-Tris, 2.5 mmol/L GSH, 65 mmol/L KCl, 7 mmol/L MgCl₂, pH 7.4 for MRP2; 158 and 10 mmol/L HEPES-Tris, 100 mmol/L KNO₃, 12.5 mmol/L Mg(NO₃)₂, and 50 mmol/L sucrose, pH 7.4 for BSEP) at 37 °C for 10 minutes. The transport was initiated by adding 125 µL 159 of pre-warmed 25 mmol/L MgATP, 3 µmol/L of E7766 in the presence or absence of inhibitors 160 (3 µmol/L of Novobioncin for BCRP, 100 µmol/L of MK-571 for MRP2, and 20 µmol/L of 161

162 Ketoconazole for MDR1 and BSEP). The transport was terminated at designated time by adding 200 µL ice-cold vesicle uptake buffer. The complete content was then rapidly filtrated using 163 multi-screen HTS vacuum manifold, followed by 5 washes and filtrations. The plate was allowed 164 to dry completely and then placed onto a 96-well receiver plate. A 50 μ L of elute solution (75%) 165 methanol containing the internal standard) was added into each assay well followed by 166 167 centrifugation at 2000 rpm for 5 minutes. This lysis-and-centrifugation procedure was repeated one more time to maximize compound extraction. The samples from two centrifugation were 168 combined and analyzed by LC-MS/MS. All experiments were run in triplicates. 169

170 The LLC-PK1 cell-based permeability of E7766 was also assessed. Porcine kidney LLC-PK1 cells were cultured at 37 °C and 5% CO2 in Medium 199 containing 10% fetal bovine 171 serum, 292 µg/mL glutamine, 0.1 mg/mL hygromycin B, and 0.05 mg/mL gentamycin. The cells 172 were seeded in HTS Transwell–96 systems (polystyrene, 4.26 mm in diameter, 0.14 cm² surface 173 area, 1.0 μ m in pore size, Corning Inc. Corning, NY) at a density of approximately 1.4×10⁶ 174 cells/mL. Culture medium was replaced on the fourth and sixth day after seeding. Cells were 175 cultured for 7 days on Transwell plates for the studies. Prior to the experiments, LLC-PK1 cells 176 were washed using transport buffer (HBSS supplemented with 10 mmol/L HEPES) and 177 178 incubated for 60 minutes. For the experiments of apical to basolateral (A–B) direction, transport buffer containing 1 µmol/L of E7766 was added into the apical compartment while transport 179 buffer with the same treatment was added into the basolateral compartment. For the experiments 180 181 of basolateral to apical (B-A) direction, transport buffer containing 1 µmol/L of E7766 was added into the basolateral compartment while transport buffer with the same treatment was 182 added into the apical compartment. The length of incubation for transport was 2 hours and 183 184 samples were stored at -70 °C or lower prior to LC-MS/MS analysis.

185 Hepatic uptake and biliary excretion of E7766 in sandwich cultured human hepatocytes 186 (SCHH)

Transporter CertifiedTM cryopreserved human hepatocytes (BioIVT, Durham, NC, USA; Donor 187 JEL) were thawed following manufacturer's instructions. Cryopreserved hepatocytes were 188 subsequently suspended in BioIVT proprietary hepatocyte seeding medium (QualGroTM Seeding 189 Medium) and seeded at a density of 0.9 million viable cells/mL onto BioCoat® 24-well cell 190 culture plates (San Jose, CA, USA). Following plating, cells were allowed to attach for 2-4 191 hours, then were rinsed and fed with warm (37°C) seeding medium. Eighteen to 24 hours later, 192 cells were fed and overlaid with QualGroTM culture medium (QTS, Durham, NC, USA) 193 supplemented with extracellular matrix Matrigel[®] (BD Biosciences, San Jose, CA, USA; 0.25 194 mg·mL⁻¹). Cells were then maintained in QualGroTM Hepatocyte Culture Medium. Hepatic 195 uptake clearance and hepatobiliary disposition of test articles were assessed on day 5 by using B-196 197 CLEAR® Technology (Swift, Pfeifer & Brouwer, 2010). Briefly, to assess uptake clearance, cell culture medium was removed, and hepatocytes were washed three times with warm Plus (+) 198 Buffer (0.3 mL per well). Immediately following washing step, dose solutions for E7766 or 199 200 comparators (0.3 mL per well) were added and incubated for 1, 5, and 10 minutes at 37°C. Following incubation period, the solutions were collected and frozen at -80°C until process for 201 202 bioanalysis. The wells were then washed three times with ice cold Plus (+) Buffer. The plates were frozen at -80 °C until bioanalysis. 203

To assess biliary clearance, cell culture medium was removed, and hepatocytes were washed twice with warm Plus (+) or Minus (-) Buffer to maintain or disrupt tight junctions, respectively. The wash solutions were removed and replaced with fresh Plus (+) Buffer or Minus (-) Buffer (0.3 mL per well). The hepatocytes were conditioned for 10 minutes at 37 °C. The conditioning solutions were removed and replaced with dosing solutions for E7766 or comparators (0.3 mL per well). Following a 20-minute incubation, the solutions were collected and frozen at -80 °C until process for bioanalysis. The wells were then washed three times with ice cold Plus (+) Buffer. The plates were frozen at -80 °C until processed for bioanalysis. All experiments were run in triplicates.

213 In vivo Pharmacokinetics

All in vivo study protocols were approved by appropriate Institutional Animal Care and Use

215 Committee. Animals were monitored during the study and provided free access to food and

216 water.

217 Pharmacokinetics in bile-duct cannulated (BDC) rats and dogs

BDC male Sprague Dawley rats (n=4) and BDC male Beagle dogs (n=3) were given E7766 as a 218 single 1 mg/kg IV dose and 0.075 mg/kg IV dose as free acid prepared in sterile PBS, 219 220 respectively. Plasma samples were collected at pre-dose and designate time points post-dose via a jugular vein, into tubes containing sodium heparin as the anticoagulant. Urine samples were 221 222 collected at intervals 0 to 4, 4 to 8, and 8 to 24 hours post-dose into collection tubes on wet ice. 223 Bile and feces (rat only) samples were collected at intervals 0 to 4, 4 to 8, and 8 to 24 hours post-224 dose into collection tubes on wet ice. All samples were stored at -70 °C or lower until LC-MS/MS analysis. 225

226 Pharmacokinetics in humanized OATP1B1/1B3 and wild type (WT) mice

E7766 was formulated in 0.5% 0.1 N HCl, 5% DMSO, 10% EtOH, 84.5% saline for studies in
WT and humanized OATP1B1/1B3 mice. Rifampicin was formulated in 0.5% 0.1 N HCl, 5%
DMSO, 10% EtOH, 84.5% saline. Age-matched OATP1B1 and OATP1B3-knockin humanized

mice (n=3) on the Oatp1a/1b-knockout background, and wild-type (WT) FVB male mice 230 (n=3/timepoint) were purchased from Taconic Biosciences (Hudson, NY, USA). Mice were 231 between 8 and 10 weeks of age (22-34 g) at the time of study. In WT mice, E7766 was 232 administered via the tail vein at a dose of 0.5 mg/kg with either vehicle or Rifampicin (30 mg/kg 233 IV). Plasma and liver samples were collected at 0.083, 0.25, 0.5, 1, 1.5, 3, 6 hours and all 234 samples were stored at -80°C until bioanalysis. In humanized mice, E7766 was administered via 235 236 the tail vein at a dose of 1 mg/kg or together with vehicle or with Rifampicin (E7766, 0.5 mg/kg; 237 Rifampicin, 10 mg/kg). Blood samples were collected at pre-dose, and 0.08, 0.25, 0.5 1, 1.5, 3, 6 238 and 24 hours post-dose via saphenous or tail vein into a heparinized capillary. The contents of the capillary were expelled onto an appropriate spot on a DBS card (FTA DMPK-B [GE 239 Healthcare, Life Sciences, WhatmanTM]). Urine and feces samples were collected from all dose 240 groups at intervals 0-8 and 8-24 hours post-dose. Samples were stored at -80°C until bioanalysis. 241

242 LC-MS/MS analysis

Cell lysates samples were extracted by 70:30 methanol:water (v:v) containing internal standard 243 (IS) 10 nmol/L ER-001229535. Plasma samples were subjected to protein precipitation with 244 methanol containing ER-001229535 as the IS. Urine, bile and feces samples were extracted via 245 salting-out assisted liquid-liquid extraction based on the methodologies described by Tang and 246 247 Weng, 2013. For analysis of E7766 and IS of ER-001229535, a Shimadzu HPLC system (Shimadzu Scientific Instruments, Columbia, MD), which consisted of an autosampler (model: 248 SIL HTc), a column compartment unit (model: CTO-20AC), a degasser (model: DGU-20A3), 249 250 two pumps (model: LC-20AD), and a high pressure switching valve (model: FCV-20AH6) was used. The mobile phase A consisted of 2 mmol/L ammonium bicarbonate in H₂O/MeOH (95/5, 251 v/v), and mobile phase B consisted of 2 mmol/L ammonium bicarbonate in MeOH/H₂O (95/5, 252

253 v/v). Aliquots (10 µL) were injected onto a Waters XBridge Oligonucleotide BEH C18 column, 130Å, 2.5 μ m (4.6 mm inner diameter \times 50 mm length) at a flow rate of 0.5 mL/min at 40 °C. 254 The temperature of the autosampler was controlled at 4 °C. The samples were analyzed on an 255 API5000 (Sciex, Framingham, MA) triple quadrupole mass spectrometer with turbospray 256 ionization (ESI) under negative ion mode. A 9 min gradient was run for E7766 and IS, with a 257 flow rate of 0.5 mL/min as follows: 0% B for 0.3 min, 0% to 100% B over 2.7 min, 100% B for 258 2 min, 100% to 0% B over 0.2 min, then re-equilibration at 0% B for 3.8 min. Analytes were 259 detected by multiple reaction monitoring (MRM) by the following mass transitions: 372.4 (M-260 2H)²⁻ >186.5 for E7766 (-38 eV collisions) and 689.3 (M-H)⁻ >134.1 for IS (-75 eV collisions). 261

262 **PBPK model and DDI simulations**

263 Whole-body PBPK modeling and simulation were performed using the population-based absorption, distribution, metabolism, and excretion simulator, Simcyp[™] (version 18, Certara, 264 Sheffield, UK). Each simulation was performed for 100 subjects (10 trials \times 10 subjects) using 265 266 the software's built-in healthy volunteer virtual population. To simulate the effect of OATP 267 inhibitors on the PK of E7766, the PBPK model for Rifampicin-SD was adopted directly from the default SimcypTM compound library. For all simulations, E7766 was administered as a single 268 intravenous dose and Rifampicin was administered as a single oral dose. Physicochemical 269 270 properties and input parameters for E7766 used for the PBPK model are summarized in Table 4.

271 Parameters of Rifampicin for the DDI simulation are summarized in Supplemental Table 4

The full-PBPK model with Method 2 (based on Rodgers and Rowland) was used to predict the volume of distribution (V_d) of E7766 (Rodgers et al., 2005; Rodgers and Rowland, 2006). A K_p scalar of 4 was applied to the prediction of human V_d. The K_p scalar was determined based on the predicted versus observed V_d of E7766 in preclinical species. Permeability-limited 276 disposition was considered for liver. The DDI simulation was run in two scenarios: 1) Hepatic uptake clearance was assigned from the transporter kinetics $(V_{\text{max}}/K_{\text{m}})$ for OATP1B1 and 277 OATP1B3 measured in the HEK293FT system, and intrinsic passive diffusion across the 278 279 sinusoidal membrane measured in SCHH studies, and scenario 2) intrinsic active uptake clearance, passive clearance on the sinusoidal membrane and efflux clearance on the canalicular 280 281 membrane, measured in the SCHH studies, were used to capture hepatobiliary disposition. In 282 both scenarios, the intrinsic uptake clearances were scaled up to physiologically relevant uptake clearance by a relative expression factor (REF) approach (Hirano et al., 2004) within Simcyp 283 284 models. Additionally, in second scenario, the intrinsic uptake clearance from SCHH was assigned to OATP1B3 ($f_t = 0.97$) to capture the DDI. Based on in vitro metabolism data using 285 286 cryopreserved human hepatocytes (data not shown), metabolic clearance was assumed to be negligible for both simulations. PK in preclinical studies suggest that E7766 is expected to be 287 eliminated from kidney via glomerular filtration. The renal clearance of E7766 was then fixed as 288 3 L/h as a product of GFR (~6 L/h in human; Lin et al. 2003) and plasma protein binding of 289 E7766 (0.5, measured data, Table 4). This fixed renal clearance also aligned well with back 290 calculation from systemic clearance and the observation from PK studies of multiple preclinical 291 292 species, where about 10% of E7766 was excreted in urine as parent compound. Sensitivity analysis was performed to evaluate changes in drug exposure and DDI due to any uncertainty in 293 the in vitro parameters. 294

295 Data analysis

The uptake velocity describes the rate of E7766 taken up by active and/or passive processes of the transporter-expressing cell or vesicles, and is calculated as follows:

298 uptake velocity = $(C \times V)/T/W$

(1)

299 where C represents the concentration of E7766 in the cellular (or vesicular) lysate (μ mol/L), V is the volume of the lysate (μL) , T is the incubation time and W is the measured cellular (or 300 vesicular) protein amount of each well (mg). 301 The OATP1B1 or OATP1B3 specific uptake velocity was calculated by subtracting mean uptake 302 velocity of E7766 in HEK293-Control cells from that of HEK293FT-OATP1B1 or HEK293FT-303 OATP1B3 cells at each of the corresponding concentration. Kinetic and statistical analyses of the 304 transport data were conducted using GraphPad Prism Ver. 7.02 (GraphPad Software, Inc., San 305 Diego, CA). Kinetic data was fit to a Michaelis-Menten model as follows: 306 307 $v = V_{max} \times S/[K_{m}+S]$ (2)where v is the OATP1B1 or OATP1B3 specific uptake velocity (pmol/mL/mg protein), S is the 308 concentration of E7766 in the uptake buffer (μ mol/L), K_m is the apparent Michaelis-Menten 309 constant (μ mol/L), and V_{max} is the apparent maximum uptake rate (pmol/min/mg protein). The in 310 vitro intrinsic clearance (CL_{int,in vitro}) was calculated as follows: 311 312 $CL_{int,in vitro} = V_{max}/K_m$ (3) The relative contribution of OATP1B1 and OATP1B3 to the hepatic uptake of E7766 was 313 assessed by the relative expression factor (REF) approach (Kunze et al., 2014). REF for each 314 315 transporter was calculated by following equations: REF_{1B1} EXPOATP1B1,HEP/EXPOATP1B1,HEK 316 = 317 (4) 318 REF_{1B3} EXPOATP1B3, HEP/EXPOATP1B3, HEK = (5) 319 where EXP represents the specific transporter expression (fmol/mg protein) determined in 320 321 primary human hepatocyte (HEP), or HEK293FT-OATP1B1 or HEK293FT-OATP1B3 cell line

322 (HEK). The expression levels of OAPT1B1 and OATP1B3 in hepatocyte and HEK293-FT overexpressing cell line are summarized in Supplemental Table 2. 323 For SCHH assays, the intrinsic hepatic uptake clearance (Liver Uptake CL_{int,T}) was determined 324 using following: 325 Uptake $CL_{int,T} = A_{Plus} (+)Buffer / (T \times C_{initial})$ 326 (6)where A_{Plus} (+)Buffer is the total accumulation of E7766 (cells + bile pocket) in SCHH after 327 incubation with Plus (+) buffer (μ mol), T is the incubation time (min), and C_{initial} is the initial 328 329 concentration of E7766 in dosing medium (µmol/L). 330 The biliary excretion index (BEI) was obtained from equation 7 and intrinsic biliary clearance (Liver Efflux CL_{int.T}) was calculated from equation 8: 331 BEI 100 $[A_{\text{Plus}}]$ 332 = \times (+)Buffer $A_{\text{Minus}(-)\text{Buffer}}]/A_{\text{Plus}}$ (+)Buffer (7)333 (8)334 Efflux $CL_{int,T} = [A_{Plus} (+)B_{uffer} - A_{Minus(-)Buffer}] / (T \times C_{initial})$ where $A_{\text{Minus}(-)\text{Buffer}}$ is cellular accumulation inside hepatocytes (cells only) after incubation with 335 Minus (–) buffer (μ mol). 336 PK parameters of E7766 were obtained by non-compartmental analysis using Phoenix 337 338 WinNonlin® Ver. 7.0.0.2535 (Certara USA, Inc., Princeton, NJ, USA). The parameters calculated were the cumulative amount of E7766 recovered in urine (Xu_(0-t)), bile (Xb_(0-t)) and 339 feces $(Xf_{(0-t)})$, which were determined as the sum of the amounts recovered in each sampling 340

interval; the percent of the administered dose excreted in urine (A_{e renal} %), bile (A_{e biliary} %) and feces (A_{e fecal} %); and the renal (CL_{renal}), biliary (CL_{biliary}) and fecal clearances (CL_{fecal}), which were calculated using the cumulative amount recovered up to the last measurable urine, bile, or feces sample along with the AUC_(0-t, last) as CL_{renal} = Xu_(0-t, last) / AUC_(0-t, last) / body weight,

- $345 \qquad CL_{biliary} = Xb_{(0-t, last)} / AUC_{(0-t, last)} / body weight and CL_{fecal} = Xf_{(0-t, last)} / AUC_{(0-t, last)} / body$
- 346 weight, respectively.

348 **Results**

349 Assessment of E7766 as a substrate of hepatic uptake transporters

350 As shown in Figure 2A, OATP1B1 and OATP1B3 showed significant active uptake of E7766 (p < 0.000001 and p = 0.000021 for OATP1B1 and OATP1B3, respectively), which could be 351 inhibited by Rifampicin (100 µmol/L; p<0.000001 and p=0.000007 for OATP1B1 and 352 OATP1B3, respectively). Active uptake of E7766 was not observed in cells expressing 353 354 OATP2B1 (p=0.11) or NTCP (p=0.11). The results indicated that E7766 is a substrate for OATP1B1 and OATP1B3 but not a substrate for OATP2B1 and NTCP. We observed differences 355 in passive uptake of E7766 with mock cells groups and this was at least partially due to the 356 differences in cell subtypes, cell engineering, culture conditions and assay conditions. 357 358 Additionally, very low passive permeability of E7766 could add further variability of passive 359 uptake with mock cells. To support the validation of in vitro assay systems, uptake activity of 360 positive control substrates was summarized in Supplemental Figure 1A.

361 The results of concentration-dependent uptake of E7766 in HEK293FT-OATP1B1, HEK293FT-OATP1B3, and HEK293FT-Control cells are summarized in Figure 3. The data 362 363 were best-fitted to a Michaelis-Menten model, and the kinetic parameters for uptake of E7766 by 364 OATP1B1 were calculated as 2.2 μ mol/L (K_m) and 27.8 pmol/min/mg protein (V_{max}). The in vitro uptake clearance (CLint, in vitro) of OATP1B1 was then calculated to be 12.6 µL/min/mg 365 protein. The $K_{\rm m}$, $V_{\rm max}$, and $CL_{\rm int,in vitro}$ of OATP1B3-mediated uptake of E7766 were estimated as 366 367 4.0 µmol/L, 81.3 pmol/min/mg protein, and 20.5 µL/min/mg protein, respectively. The relative expression factors (REFs) for OATP1B1 and OATP1B3 were calculated to be 0.1 and 2.8, 368 respectively using the measured expression of these transporters in the overexpressing cell lines 369 and the reported expression levels in human hepatocytes from Schaefer et.al, 2012 370

(Supplemental Table 2). We decided to use the transporter expression reported by Schaefer et.al,
2012 because the methodology used to extract the membrane protein and measure the protein
content aligned with the methodology used to measure transporter expression in our HEK293FT
overexpressing system.

375 Assessment of E7766 as a substrate of biliary efflux transporters

376 E7766 was incubated with either MDR1, BCRP, BSEP or MRP2 expressing or control vesicle 377 membranes. As shown in Figure 2B, E7766 did not show transporter-mediated uptake activities in MDR1 (p>0.99), BCRP (p=0.17) and BSEP (p=0.45) expressing vesicles. Incubation of 378 E7766 with MRP2-expressing vesicles resulted in greater uptake activity than that with control 379 vesicles with an uptake ratio of 23 and a p-value of 0.00014. Co-incubation of E7766 and 380 381 positive control inhibitor MK-571 (100 µmol/L) with MRP2 expressing vesicles, decreased the 382 uptake ratio from 23 to 1.1 (p=0.00014). The results indicated that E7766 is a substrate of efflux 383 transporter MRP2, but not a substrate of MDR1, BCRP or BSEP (Figure 2B). The transporter 384 activity of positive control substrates for MDR1, MRP2, BCRP and BSEP is shown in Supplemental Figure 1B. The transcellular permeability of E7766 was assessed in LLC-PK1 385 386 cells. The results, as shown in Supplemental Table 1 indicated that E7766 exhibited very low permeability in LLC-PK1 cells ($P_{app} < 1 \times 10^{-6}$ cm/s). 387

388 Evaluation of hepatic uptake and biliary excretion of E7766 in SCHH

The transporter-mediated hepatic uptake potential of E7766 was evaluated in SCHH prepared from one donor (JEL). The intrinsic hepatic uptake clearance of E7766 (uptake $CL_{int,T}$) at 4 °C was markedly decreased to <7.6% of that at 37 °C at two lower dose levels (0.3 and 1.0 μ mol/L) (Table 1). The uptake $CL_{int,T}$ of E7766 across all dose levels dropped rapidly from 1 to 5 minutes (Table 1). These results suggested hepatic uptake was rapidly achieving near maximal accumulation within 5 minutes. In addition, the uptake $CL_{int,T}$ decreased dramatically at 10 µmol/L across all exposure periods compared to uptake $CL_{int,T}$ measured at 0.1 µmol/L and 3 µmol/L suggesting hepatic uptake was saturated at concentration of >1.0 µmol/L (Table 1). Taken together, these results suggested that hepatic uptake of E7766 was primarily mediated by a relatively fast active uptake mechanism.

As shown in Table 1, following 20-minute exposure, the intrinsic biliary efflux clearance 399 (efflux CL_{int,T}) decreased dramatically at 10 µmol/L compared to those at doses of 0.3 and 1 400 µmol/L suggesting hepatobiliary transport of E7766 was saturated at concentration of >1.0 401 402 µmol/L. The BEI of E7766 ranged from 70.9 to 86.2% across the concentration range assessed. These BEI values were comparable to d8-TCA (72.6%), a model bile acid, and was ~2-fold 403 greater than the reference compound rosuvastatin (BEI = 42.7%). The difference in BEI for 404 Rosuvastatin and d8-TCA/E7766 are likely due to differences in uptake and efflux mechanisms 405 as well as kinetics of uptake and efflux of these compounds in the SCHH system. Overall, these 406 results suggested the biliary excretion of E7766 is mediated by a saturable mechanism and with a 407 relatively high BEI value. 408

409 Pharmacokinetics of E7766 in bile-duct cannulated BDC rats and dogs

The PK of E7766 in BDC rats (Table 2) was characterized by high $CL_{tot.p}$ (6.50 L/h/kg) and moderate V_{ss} (2.47 L/kg). The mean $Xu_{(0-t)}$ and $Xb_{(0-t)}$ up to 24 hours postdose were 38,600 and 261,000 ng, respectively, which corresponds to 13.7% (A_{e renal}) and 92.1% (A_{e biliary}) of the total dose administered, respectively. The mean cumulative amount of E7766 excreted in feces ($Xf_{(0-t)}$) up to 24 hours postdose was 991 ng, which correspond to 0.4% of the total dose administered (A_e fecal). Mean CL_{renal}, CL_{biliary} and CL_{fecal} of E7766 in BDC rats were 0.895 L/h/kg, 6.04 L/h/kg and 0.0227 L/h/kg, respectively. The PK of E7766 in BDC dogs (Table 2) was characterized by moderate total plasma clearance ($CL_{tot,p}$, 1.29 L/h/kg) and limited volume of distribution (V_{ss} , 0.553 L/kg). The mean cumulative amounts of unchanged E7766 excreted in urine ($Xu_{(0-t)}$) and bile ($Xb_{(0-t)}$) up to 48 hours postdose were 33,400 and 625,000 ng, respectively, which correspond to 5.0% ($A_{e renal}$) and 87.9% ($A_{e biliary}$) of the total dose administered, respectively. Mean renal (CL_{renal}) and biliary ($CL_{biliary}$) clearances of E7766 in dogs were 0.0528 L/h/kg and 1.19 L/h/kg, respectively.

423 Pharmacokinetics of E7766 in OATP1B1/1B3 humanized and wild type (WT) mice

The plasma and liver PK of E7766 in WT mice was assessed with or without coadministration of 424 Rifampicin (Figure 4). The unbound concentration-time profiles of Rifampin in wild type and 425 humanized mice are shown in Supplemental Figure 3. The plasma PK of E7766 in WT was 426 427 characterized by high $CL_{tot,p}$ (8.93 L/h/kg) and moderate V_{ss} (1.66 L/kg) (Table 3). In the presence of Rifampicin, the plasma exposure (AUCtotal) of E7766 in WT mice increased 5.4-fold 428 with a corresponding decrease in CL_{tot.p}. The liver exposure to E7766 was comparable in WT 429 430 mice with or without coadministration of Rifampicin indicating that Rifampicin only affects the 431 plasma exposure and that liver exposure is unchanged by Rifampicin. However, the liver-to-432 plasma ratio $K_{p,total}$ of E7766 in Rifampicin treated animals decreased by 82% indicating a strong 433 inhibition of Oatp mediated hepatic uptake of E7766 in mice (Table 3). The dose normalized plasma exposure (AUC_{total}/Dose) and CL_{tot.p} were compared between WT mice (AUC_{total}/Dose: 434 112 ng/h/mL⁻¹/[mg/kg] and CL_{tot,p}: 8.93 L/h/kg) and OATP1B1/1B3 humanized mice 435 (AUC_{total}/Dose: 126 ng/h/mL⁻¹/[mg/kg] and CL_{tot.p}: 9.20 L/h/kg). The dose normalized AUC in 436 humanized mice increased 4.8-fold after coadministration with Rifampicin, which aligned with 437 the increase in AUC (5.4-fold) in WT mice. We also assessed the percentage of the E7766 dose 438 excreted in the urine and feces in the above studies (Figure 4). The dose excreted in the feces in 439

both WT and OATP1B1/1B3 humanized mice decreased to a similar extent (3-fold lower in WT
mice and 4.6-fold lower in humanized mice) in the presence of Rifampicin. This decrease is in
line with the corresponding increase in systemic exposure to E7766 in the presence of
Rifampicin.

444 PBPK modeling and DDI simulation of E7766

The predicted plasma PK and systemic clearance as well as AUC ratio of E7766 in the presence 445 and absence of Rifampicin are presented in Figure 5 and Table 5. In scenario one of the DDI 446 simulation, active uptake clearances measured as $J_{\text{max}}/K_{\text{m}}$ in HEK293 cells were assigned to 447 OATP1B1 and OATP1B3, and the passive sinusoidal and biliary efflux clearances were taken 448 from the SCHH experiment. Based on the REF factor and the in vitro uptake kinetics, the f_t for 449 450 OATP1B3 and OATP1B1 were predicted to be 0.97 and 0.02, respectively, thus suggesting that OATP1B3 plays a predominant role in the hepatic uptake of E7766 (Figure 5A). The 451 contribution of passive sinusoidal diffusion clearance to the overall uptake CL of E7766 was 452 negligible (1%, Figure 5A). This simulation showed that the plasma AUC_{total} increases by 2.77-453 fold whereas the C_{max} in the presence of Rifampicin is unchanged (Figure 5B). The free liver 454 intracellular C_{max} of E7766 in the presence of Rifampicin decreases by 31.1% and E7766 455 concentration further decreases to 72.6% at 1 hour after dosing due to impairment of OATP1B 456 function. However, as shown in Figure 5C after 1 hour, the liver intracellular concentration starts 457 to increase at later time points and therefore results in an unchanged liver intracellular AUC_{free} 458 (69.06 nmoL/h/L, Table 5) in presence of Rifampicin compared to Rifampicin free group (76.19 459 nmoL/h/L, Table 5). This increase of liver concentrations at later time points is due an increase in 460 461 the systemic exposure of E7766 in the presence of Rifampicin. A sensitivity analysis was performed for the in vitro parameters with uncertainty. As shown in Figure 5D-F, the change in 462

463 AUC ratio ranged from 1.0 to 2.6 when the REF or kinetic parameters for OATP1B3 were varied. The AUC ratio remained unchanged when the REF or kinetic parameters for OATP1B1 464 was varied indicating that the DDI was not sensitive to changes in J_{max} , K_m and REF for 465 OATP1B1. It is noteworthy that, AUC ratio first increases along with the increase of OATP1B3 466 REF (when OATP1B3 REF< 3) and then starts to drop as OATP1B3 REF increased further until 467 468 AUC ratio becomes ultimately close to unity (Figure 5D). One potential reason for this pattern maybe that, the hepatic uptake clearance increases when the OATP1B3 REF increased and will 469 result in a larger DDI magnitude, i.e., a greater AUCR in the beginning when REF is in a 470 471 relatively low range. However, as the OATP1B3 REF increases further (above three), the intrinsic uptake clearance will exceed hepatic blood flow and become a blood-flow rate limited 472 process. Therefore the AUC is not readily affected by inhibition of uptake clearance. We 473 speculate that another explanation may be that E7766 is being cleared away from the transporter 474 binding site very rapidly when REF increases further. Thus there is not enough duration of 475 exposure for E7766 (given as i.v. bolus dose) to have interaction with orally administered 476 Rifampicin, which needs time to get to the interaction site in liver. 477

In the second scenario, DDI was simulated using active uptake, passive sinusoidal uptake and biliary efflux clearances measured in SCHH experiment. In this simulation, we observed similar results for both PK profile and DDI potential of E7766 as victim compared to the first scenario. The comparison between two different scenarios are summarized in Table 5. Simulation showed that the plasma AUC increases by 2.59-fold whereas the C_{max} in the presence of Rifampicin is unchanged. The liver AUC_{free} calculated by free intracellular concentrations remained unchanged in the presence of Rifampicin with a liver AUC_{free} ratio of 0.86. The

- 485 consistency of prediction from two scenarios which adopted experimental data from two
- 486 independent approaches suggests that the PBPK model is mechanistically sound.

488 Discussion

489 E7766 is a macrocycle-bridged dinucleotide under development as an immuno-oncology drug to be used as a single agent or in combination with other standard of care therapies. For several 490 drugs such as pravastatin which are cleared primarily via biliary excretion, hepatic uptake is in 491 fact the rate limiting step (Nakai et al., 2001), and inhibition of these uptake processes or 492 polymorphisms in the hepatic uptake transporters may lead to clinically relevant change in the 493 494 PK of drugs (Chen et al., 2018). Therefore, in vitro and in vivo studies were conducted for E7766 to systemically investigate drug transporters involved in its systemic clearance and to 495 predict clinical DDI potential using PBPK models. 496

497 PK and excretion studies of E7766 were first conducted using BDC rats and BDC dogs. The results confirmed that biliary excretion plays predominant role in systemic clearance of 498 499 E7766. To further study the clearance mechanisms of E7766, DDI studies with Rifampicin were 500 conducted with OATP1B1/1B3 humanized and WT mice. Coadministration with Rifampicin in OATP1B1/1B3 humanized mice as well as WT mice resulted in an approximately 5-fold 501 decrease in plasma clearance of E7766. We also measured the liver exposure of E7766 with and 502 without coadministration with Rifampicin in WT mice. While liver AUC was comparable 503 504 between mice with or without Rifampicin, the observed decrease in liver/plasma ratio (liver $K_{p,total}$) in WT mice in the presence of Rifampicin is consistent with hepatic OATP-mediated 505 uptake. Studies in bile-duct cannulated dogs and rats show that biliary excretion of unchanged 506 drug is the major route of clearance in preclinical species. Fecal excretion of unchanged drug 507 508 was also observed in humanized and WT animals and excretion into the feces decreased 509 substantially in animals where liver OATP/oatp function was inhibited. Taken together these 510 results suggest that E7766 is cleared from systemic circulation primarily via active uptake into

the liver by OATP/oatp and then excreted unchanged into the bile. Previous reports have shown that hepatic expression of OATP1B1 in the humanized mice was lower than in human liver whereas the expression of OATP1B3 was 3-fold higher than in human liver (Higgins et al., 2014). These differences in the expression could lead to the overestimation of the contribution of OATP1B3 on the systemic exposure of OATP substrates in humanized mice. However, OATP1B1/1B3 humanized mice may still be useful in qualitatively determining whether hepatic OATP can impact systemic exposure and hepatic distribution of substrates.

518 To prospectively predict clinical DDI potential for E7766 as the victim drug, we used in 519 vitro kinetic data generated from transporter overexpressing cell lines coupled with REF approach (scenario one) and Clint data from SCHH coupled with REF approach (scenario two) to 520 build "bottom-up" full PBPK models and run DDI simulations. DDI simulation with Rifampicin 521 522 suggests that Rifampicin may cause about 2-3 fold increase in plasma AUC in both scenarios, 523 indicating that the current PBPK model is mechanistically sound. Similar to the findings in mice 524 treated with Rifampicin, PBPK simulation showed that the intracellular free liver AUC did not change with treatment with Rifampicin, however the liver-to-plasma ratio decreased in the 525 presence of Rifampicin. Previously reported PBPK approaches suggested the need for empirical 526 527 scaling factors for hepatic active uptake to recover human PK of several OATP substrates (Jones et al., 2012; Watanabe, et al., 2009). These scaling factors are derived from "top down" 528 approaches and are often compound specific (Varma et al., 2013). Hence the model developed 529 530 here will need to be verified and E7766 specific scaling factors will be derived once clinical PK and DDI data for E7766 are available. 531

532 For prospective DDI assessment, a sensitivity analysis of parameters that have high 533 uncertainty is important. For transporter-mediated DDIs, there is significant uncertainty due to 534 the limited understanding of quantitative translation of in vitro transporter kinetics to the clinical scenario. Hence we conducted a sensitivity analysis of the in vitro J_{max} , K_m and REF values. The 535 sensitivity analysis results showed that AUC ratio is less sensitive to changes in the kinetic 536 parameters for OATP1B1 than those of OATP1B3 due to predominant role of OATP1B3 in the 537 overall clearance. On the other hand, based on f_t of E7766 for OATP1B1 and the sensitivity 538 analysis, we can conclude that the pharmacokinetics of E7766 is less likely to be influenced by 539 polymorphisms in OATP1B1. While the impact of genetic polymorphisms of OATP1B1 on the 540 PK/PD of OATP1B substrates has been well documented (Niemi et al., 2011), that of OATP1B3 541 542 polymorphisms has not been clearly reported. Reduced uptake of glibenclimide and glipizide by OATP1B3 in HEK cells expressing OATP1B3 (699G > A) was recently reported (Yang et al, 543 2018). However, there are no reported clinical studies to support these in vitro observations. It is 544 however advisable to genotype patients and healthy volunteers for any potential OATP1B3 545 polymorphisms to understand any inter-individual variability in E7766 exposure. 546

E7766 was also identified as a novel substrate of MRP2, an efflux transporter expressed 547 on the canalicular membrane of human hepatocytes. MRP2 is essential for hepatobiliary and 548 renal elimination of many anionic substrates, including drugs and conjugates such as bilirubin 549 glucuronides (Nies and Keppler, 2007). It was reported that Rifampicin when dosed 600 mg 550 orally may inhibit MRP2-mediated biliary excretion of (15R)-¹¹C-TIC-Me (Takashima et al., 551 2012). However, it is likely that the OATP mediated uptake rather than MRP2 mediated efflux 552 553 influences the systemic exposure of E7766. This conclusion is based on, 1) ECCS classification which states that hepatic uptake will be the major contributor to the clearance of class 3B 554 555 compounds and, 2) Others reported (Watanabe, et al., 2009) that the impairment of MRP2 would 556 only affect the liver AUC but has no impact on plasma AUC if the compound is uptake limited.

DMD Fast Forward. Published on December 18, 2020 as DOI: 10.1124/dmd.120.000125 This article has not been copyedited and formatted. The final version may differ from this version.

557

558

559

560

To the best of our knowledge, no systemic DDI has been attributed to MRP2, and there is no evidence that MRP3 or MRP4 should be examined or that there is a likelihood of DDI for a substrate of MRP2 (Hillgren et al., 2013). Further studies are warranted to investigate whether other dinucleotide NCEs are also substrates of OATP1Bs and MRP2. A recent paper published by Luteijn and coworkers (Luteijn

561 562 et al., 2019) identified SLC19A1 (folate-organic phosphate antiporter) as the major transporter to facilitate cellular uptake of cyclic dinucleotides such as 2'3'-cGAMP into THP-1 cells and 563 therefore has implications for the immunotherapeutic treatment of cancer. The uptake of 2'3'-564 565 cGAMP was inhibited by methotrexate and sulfasalazine, inhibitors of SLC transporters. OATP1B1, OATP1B3 and other OATP transporters are also found in multiple cancer cells 566 including breast cancer, colon cancer, liver cancer, pancreatic cancer, prostate cancer, testicular 567 568 cancer, and thyroid cancer (Pressler et al., 2011; Wlcek et al., 2008). Given that cellular permeability of E7766 or its analogs could be low due to their physiochemical properties, 569 additional investigation into whether other analogs of E7766 are substrates of OATP1B1/1B3, 570 SLC19A1 or other OATP transporters expressed in hepatocytes, immune cells or cancer cells can 571 provide insight into ADME properties and pharmacological function of these novel NCEs. 572

In summary, our data show that transporter-mediated hepatic uptake is the major contributor to the overall systemic clearance of E7766. Based on the estimated f_t for OATP1B3 and OATP1B1 we conclude that OATP1B3 plays a predominant role in the hepatic uptake of E7766. The findings reported here have a significant influence on the design of clinical pharmacology program for E7766. Due to near complete recovery of unchanged E7766 observed in preclinical animal studies, the clinical protocols emphasized the need for collecting urine and fecal samples from patient volunteers in Phase I studies to measure the recovery of E7766 in 580 early clinical studies, which will give us useful information about renal and biliary clearances of 581 E7766 in humans. This information could help design an appropriate human ADME study and accelerate clinical development of E7766. Since nonclinical studies have identified transporters 582 583 responsible for clearance of E7766, appropriate clinical DDI studies can be designed and the PBPK model developed here can be used to predict DDI with perpetrators or co-administered 584 therapies. Finally, the results collected from current studies may also shed light on 585 pharmacokinetics and pharmacodynamics of other compounds from this class of macrocycle-586 bridged dinucleotides. 587

588 Acknowledgements

- 589 The authors would like to thank Kazutomi Kusano, Takafumi Komori, Yoshitane Nozaki, Naomi
- 590 Wakayama, Saki Izumi and Raku Shinkyo from Eisai Co. LTD., Tsukuba, Japan for review and
- 591 helpful scientific discussions during the preparation of this manuscript.

592 Authorship Contributions

- 593 Participated in research design: Jiang, Dixit, Hart, Lai
- 594 Conducted Experiments: Jiang, Hart, Burgess
- 595 Contributed new reagents or analytic tools: Kim
- 596 Performed Data analysis: Jiang, Dixit, Hart
- 597 Wrote or contributed to the writing of the manuscript: Jiang, Dixit

599 **References**

- 600 Chen Y, Zhu R, Ma F, Mao J, Chen EC, Choo EF Sahasranaman S and Liu L (2018) Assessment of
- 601 OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK)

modeling - a case example. *Biopharm Drug Dispos* 39: 420-430.

- 603 Corrales L, McWhirter SM, Dubensky TW, Jr. and Gajewski TF (2016) The host STING pathway at the
- 604 interface of cancer and immunity. J Clin Invest 126: 2404-2411.
- 605 Duan P, Zhao P and Zhang L (2017) Physiologically Based Pharmacokinetic (PBPK) Modeling of
- 606 Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). Eur J Drug Metab
- 607 *Pharmacokinet* 42: 689-705.
- 608 EMA (2012) Guideline on the investigation of drug interactions.
- 609 Endo A, Kim DS, Huang KC, Hao M, Mathieu S, Choi HW, Majumder U, Zhu X, Shen Y, Sanders K,
- 610 Noland T, Chandra D, Chen Y, Tendyke K, Loiacono K, Kolber-Simonds D, Jiang R, Dixit V, Hutz J,
- 611 Wang J, Bao X, Fang F and Sarwar N (2019) Discovery of E7766: A representative of a novel class of
- 612 macrocycle-bridged STING agonists (MBSAs) with superior potency and pan-genotypic activity. *Cancer*
- 613 *Res* 79: Abstract nr 4456.
- FDA (2017) In Vitro Metabolism- and Transporter- Mediated Drug-Drug Interaction Studies Guidancefor Industry
- Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC and Zamek-Gliszczynski MJ(2014) Utility
 of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated
 pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and
 carboxydichlorofluorescein. *Drug Metab Dispos* 42: 182-192.
- 620 Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L and International
- 621 Transporter Consortium (2013) Emerging transporters of clinical importance: an update from the
- 622 International Transporter Consortium. *Clin Pharmacol Ther* 94: 52-63.

- Hirano M, Maeda K, Shitara Y and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8
- 624 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146.

Jiang R, Dong J, Li X, Du F, Jia W, Xu F, Wang F, Yang J, Niu W and Li C (2015) Molecular

- 626 mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-
- 627 perpetrated herb-drug interactions on OATP1B3. *Br J Pharmacol* 172: 1059-1073.
- 528 Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, EI-Kattan A, Houston JB,
- 629 Galetin A and Fenner KS (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-
- 630 mediated disposition in humans from sandwich culture human hepatocyte data. *Drug Metab Dispos* 40:
- **631** 1007-1017.
- Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M and
 Hall SD (2015) Physiologically based pharmacokinetic modeling in drug discovery and development: a
- 634 pharmaceutical industry perspective. *Clin Pharmacol Ther* 97: 247-262.
- Huang KC, McGrath S, Chandra D, Wu J, Kim DS, Albu D, Ingersoll C, Tendyke K, Loiacono K,
- 636 Noland T, Verbel D, Zhang C, Hao MH, Matijevic M, Dixit V, Hukkanen RR, Hutz J, Wang J, Fang F,
- 637 Bao X, Kolber-Simonds D, Akram M and Sarwar N.(2019) Discovery and characterization of E7766, a
- novel macrocycle-bridged STING agonist with pan-genotypic and potent antitumor activity through
 intravesical and intratumoral administration. *Cancer Res* 79: Abstract nr 3269.
- 640 Kunze A, Huwyler J, Camenisch G and Poller B (2014) Prediction of organic anion-transporting
- 641 polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and
- 642 activity data. Drug Metab Dispos 42: 1514-1521.
- Lin J, Knight EL, Hogan ML and Singh AK (2003). A comparison of prediction equations for estimating
- 644 glomerular filtration rate in adults without kidney disease. *J Am Soc Nephrol* 14: 2573-2580.
- Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, McWhirter SM, Katibah GE, Corn
- 546 JE, Woodward JJ and Raulet DH (2019). SLC19A1 transports immunoreactive cyclic dinucleotides.
- 647 *Nature* 573: 434-438.

- 648 Marloyle M, Lawler SE, Berger G (2019) Current patent and clinical status of stimulator of interferon
- 649 genes (STING) agonists for cancer immunotherapy. *Pharm. Pat. Anal* 8: 87-90
- 650 Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T and Nishimura K (2001) Human liver-specific
- organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. *J Pharmacol Exp Ther* 297: 861-867.
- Niemi M, Pasanen MK and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a
 genetically polymorphic transporter of major importance for hepatic drug uptake. *Pharmacol Rev* 63:
 157-181.
- Nies AT and Keppler D (2007) The apical conjugate efflux pump ABCC2 (MRP2). *Pflugers Arch: Euro J Physio* 453: 643-659.
- Pressler H, Sissung TM, Venzon D, Price DK and Figg WD (2011) Expression of OATP family members
 in hormone-related cancers: potential markers of progression. *PLoS One* 6: e20372.
- 660 Rodgers T, Leahy D, and Rowland M (2005) Physiologically based pharmacokinetic modeling 1:
- predicting the tissue distribution of moderate-to-strong bases. *J Pharm Sci* 94:1259-1276.
- Rodgers T and Rowland M (2006) Physiologically based pharmacokinetic modelling 2:
 predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. *J Pharm Sci*95:1238-1257.
- Rodgers T and Rowland M (2007) Mechanistic approaches to volume of distribution predictions:
 understanding the processes. *Pharm Res* 24:918-933.
- 667 Swift B, Pfeifer ND and Brouwer KL (2010) Sandwich-cultured hepatocytes: an in vitro model to
 668 evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. *Drug Metab Rev* 42: 446669 471.
- Takashima T, Kitamura S, Wada Y, Tanaka M, Shigihara Y, Ishii H, Ijuin R, Shiomi S, Nakae T,
 Watanabe Y, Cui Y, Doi H, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y and Watanabe Y (2012) PET

- 672 imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me. *J Nucl Med* 53:
 673 741-748.
- Tang YQ and Weng N (2013) Salting-out assisted liquid-liquid exraction for bioanalysis. *Bioanalysis* 5:
 1583-1598.
- 676 Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF and Kumar V (2013) Mechanistic modeling to
- predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. *Pharm Res* 30: 1188-
- **678** 1199.
- 679 Varma MV, Steyn SJ, Allerton C and El-Kattan AF (2015) Predicting Clearance Mechanism in Drug
- 680 Discovery: Extended Clearance Classification System (ECCS). *Pharm Res* 32: 3785-3802.
- 681 Wang Q, Zheng M and Leil T (2017) Investigating Transporter-Mediated Drug-Drug Interactions Using a
- Physiologically Based Pharmacokinetic Model of Rosuvastatin. *CPT Pharmacometrics Syst Pharmacol* 6:
 228-238.
- Watanabe T, Kusuhara H, Maeda K, Shitara Y and Sugiyama Y (2009) Physiologically based
 pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in
 humans. *J Pharmacol Exp Ther* 328: 652-662.
- 687 Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G and Jaeger W (2008) Altered expression of
- organic anion transporter polypeptide (OATP) genes in human breast carcinoma. *Cancer Biol Ther* 7:
 1450-1455.
- 690 Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN,
- Fitzgerald KA, Alegre ML, Gajewski TF (2014) STING-dependent cytosolic DNA sensing mediates
- 692 innate immune recognition of immunogenic tumors. *Immunity* 41: 830-842.
- 693 Yang F, Liu L, Chen L, Liu M, Liu F, Xiong Y, Hu X and Xia C (2018) OATP1B3 (699G>A) and
- 694 CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide.
 695 *Scientific Reports* 8:18063.
- 696 Yoshikado T, Toshimoto K, Maeda K, Kusuhara H, Kimoto E, Rodrigues AD, Chiba K and Sugiyama Y
- 697 (2018) PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions

- 698 Involving Inhibition of Hepatic OATP1B1 and OATP1B3. CPT: Pharmacometrics Syst Pharmacol 7:
- **699** 739-747.

701 Figure Legends

702

Figure 1: Structure of E7766, a novel agonist of STING pathway

Figure 2: Phenotyping of hepatobiliary transporters involved in the disposition of E7766. (2A)

- 705 Uptake of E7766 was evaluated in SLC transporter-expressing HEK293 cells; (2B) Transport of
- 706 E7766 was evaluated on ABC transporter-expressing membrane vesicles.

Figure 3: In vitro transporter kinetics of E7766 were measured in HEK-293 cells expression
OATP1B1 or OATP1B3. (3A) Kinetics and Michaelis-menten parameters of OATP1B1mediated uptake of E7766; (3B) Kinetics and Michaelis-menten parameters of OATP1B3mediated uptake of E7766.

Figure 4: Pharmacokinetics and disposition of E7766 following intravenous administration in 711 712 wild type and OATP1B1/1B3 humanized mice. (4A) Plasma concentrations of E7766 were measured with or without coadministration with Rifampicin following intravenous 713 administration of E7766 and Rifampicin. (4B) Blood concentrations of E7766 were measured 714 715 with or without coadministration with Rifampicin following intravenous administration of E7766 716 and Rifampicin. (4C) Excretion with or without coadministration with Rifampicin of E7766 in 717 urine, bile and feces was determined following intravenous administration of E7766 and Rifampicin. (WT: wild type mouse; Hu: Humanized mouse) 718

Figure 5 Summary of PK parameters and DDI profile of E7766 from PBPK model. (5A) Contribution of passive diffusion, OATP1B1 and OATP1B3-mediated uptake to overall hepatic uptake clearance of E7766. Simulated plasma (5B) and liver (5C) concentration-time profiles of E7766 following i.v. administration of 1 mg dose with and without 600 mg oral dose of

- 723 Rifampicin. Sensitivity analysis of changes in E7766 area under the curve ratio (AUCR) as a
- function of REF (5D) and kinetic parameters for OATP1B1 (5E) and OATP1B3 (5F).

726 Tables

727 **Table 1**

728 Summary of in vitro parameters for E7766 estimated from the sandwich cultured human hepatocytes

Test Article	Target Concentration (µmol/L)	Temperature	Time (min)	Uptake CL _{int,T} (µL/min/10 ⁶ cells)	Efflux CL _{int,T} (µL/min/10 ⁶ cells)	BEI %
			1 5	7.69 ± 0.47 3.83 ± 0.26	_	
	0.3	37°C	10	3.12 ± 0.26		
			20	Not determined	2.05 ± 0.07	85.2 ± 1.7
		4°C	10	0.13 ± 0.00	—	—
	1.0	37°C	1	5.46 ± 0.10	_	—
			5	2.70 ± 0.14	-	-
E7766			10	1.85 ± 0.13	_	
Linoo			20	Not determined	1.42 ± 0.08	86.2 ± 0.40
		4°C	10	0.14 ± 0.02	_	—
	10.0	37°C	1	1.22 ± 0.11		-
			5	0.47 ± 0.02	-	-
			10	0.33 ± 0.01	_	—
			20	Not determined	0.15 ± 0.01	70.9 ± 1.3
		4°C	10	0.58 ± 0.73	-	-
d8-TCA	5	37°C	10	14.2 ± 0.82	11.0 ± 1.74	72.6 ± 5.8
		4°C		0.27 ± 0.02	—	—
Rosuvastatin	10	37°C	10	6.22 ± 0.31	2.23 ± 0.38	42.7 ± 5.8
		4°C]	0.21 ± 0.04	-	-

Uptake CL_{int,T}, intrinsic hepatic uptake clearance; Efflux CL_{int,T}, intrinsic biliary efflux clearance; BEI, biliary excretion

730 index; d8-TCA, deuterium-labeled sodium taurocholate. Values represent the means \pm SD (n = 3)

731

733 **Table 2**

734 Disposition of E7766 in bile duct cannulated (BDC) rat and dog following intravenous bolus administration

D	BDC Rat IV bolus,	Dog IV bolus,	
Dose	1 mg/kg	0.075 mg/kg	
CL _{tot,p} (L/h/kg)	6.50 ± 0.429	1.29 ± 0.369	
V _{ss} (L/kg)	2.47 ± 0.849	0.553 ± 0.345	
A _{e renal} (%)	13.7 ± 2.80	4.96 ± 4.37	
CL _{renal} (L/h/kg)	0.895 ± 0.189	0.0528 ± 0.0293	
A _{e biliary} (%)	92.1 ± 7.26	87.9 ± 30.5	
CL _{biliary} (L/h/kg)	6.04 ± 0.798	1.19 ± 0.637	
A _{e fecal} (%)	0.366 ± 0.208	-	
CL _{fecal} (L/h/kg)	0.0227 ± 0.0138	-	

735 $CL_{tot,p}$, total plasma clearance; V_{ss} , distribution volume at steady state; $A_{e renal}$, amount excreted in urine; CL_{renal} , renal

736 excretory clearance; A_{e biliary}, amount excreted in bile; CL_{biliary}, hepatobiliary excretory clearance; A_{e fecal}, amount excreted

737 in feces; CL_{fecal} , fecal excretory clearance. Values represent the means \pm SD (n = 4 for BDC rats and n = 3 for dogs)

739 **Table 3**

740	Liver and systemic exposure of	E7766 in wild type and humanized	l mice in the presence or the absence	of Rifampicin.
-----	--------------------------------	----------------------------------	---------------------------------------	----------------

Parameters	WT Mice 0.5 mg/kg E7766	WT Mice 0.5 mg/kg E7766 +Rifampicin	Hu Mice 1.0 mg/kg E7766	Hu Mice 0.5 mg/kg E7766 +Rifampicin
AUC _{total} (ng·h/mL)	56.0	300	126 ± 48.7	302 ± 92.2
AUC _{total} /Dose (ng·h/mL/[mg/kg])	112	600	126 ± 48.7	604 ± 184
CL _{tot,p} (L/h/kg)	8.93	1.72	9.20 ± 4.65	1.80 ± 0.619
V _{ss} (L/kg)	1.66	0.520	5.93 ± 5.96	1.29 ± 0.243
Liver AUC _{total} (ng·h/g)	4460	4250	_	-
Liver K _{p,total}	79.6	14.2	—	—

741 WT, Wild type mouse; Hu, OATP1B1/OATP1B3 humanized mouse; AUC_{total}, area under the total plasma concentration-

time curve; AUC_{total}/Dose, area under the total plasma concentration-time curve normalized by dose; CL_{tot,p}, total plasma

rearance; V_{ss}, distribution volume at steady state; Liver AUC_{total}, area under the total liver concentration-time curve; Liver

744 $K_{p,total}$, total liver-to-plasma concentration ratio. Values represent the means \pm SD (n = 3)

Table 4			Dowr
Summary of input parameters used t	to build the PBPK	C model for E776	6.
Parameter	Scenario one	Scenario two	Source
PhysChem and Blood Binding			in the second se
Mol Weight (g/mol)	746	746	Calculated
log P	1.31	1.31	Calculated Cf. Celculated Cf. Celcul
Compound Type	Monoprotic	Monoprotic	
Compound Type	Acid	Acid	Calculated
рКа	3.41	3.41	Calculated
B/P	0.55	0.55	Measured In Sector Action Action Sector Action Sector Action Action Sector Action Sector Action Sector Action Sector Action Sector Action Acti
fu	0.50	0.50	Measured
Distribution Model	Full PBPK	Full PBPK	April 18, 2024
	Model	Model	, 202
V _{ss} (L/kg)	0.637	0.637	SimCYP predicted (Method 2, the Rodgers-Rowland method)
<i>K</i> _p scalar	4.0	4.0	fitted based on preclinical data, see Methods for details
CL _{renal} (L/h)	3.0	3.0	Estimate as $f_u \times GFR$
Hepatic Transport (permeability-limi	ted liver module)		
Passive diffusion CL _{PD} (mL/min/10 ⁶	0.00013	0.00013	Obtained from E7766 uptake measured at 0.3 µmol/L at 4 °C with SCHH model (Table 1)
cells)	0.00013	0.00015	
fuIW	1.00	1.00	SimCYP predicted
fuEW	0.657	0.657	SimCYP predicted

J _{max} (pmol/min/10 ⁶ cells) for OATP1B1	8.34	_	V_{max} in the unit of pmol/min/mg protein (Figure 3) was converted to $\overline{V}_{\text{max}}$ in the unit pmol/min/10 ⁶ cells by incorporating measured protein abundance data of HEK293 cells \overline{E} .3 mg protein per 10 ⁶ HEK293 cells)
$K_{\rm m}$ (µmol/L) for OATP1B1	2.20	—	Obtained from transporter kinetic assays (Figure 3)
$f_{\rm uinc}$ for OATP1B1	1.00	-	SimCYP predicted
REF for OATP1B1	0.10	—	Calculated by Equation 4, see Supplemental Table 2 for details of transporter protein expression.
J _{max} (pmol/min/10 ⁶ cells) for OATP1B3	24.39	_	Figure 3. Units were converted as shown above for OATP1B1
$K_{\rm m}$ (µmol/L) for OATP1B3	3.97	-	Obtained from transporter kinetic assays (Figure 3)
$f_{\rm uinc}$ for OATP1B3	1.00	1.00	SimCYP predicted
REF for OATP1B3	2.80	—	Calculated by Equation 5, see Supplemental Table 2 for details of transporter protein expression. \subseteq
Uptake CL _{int,T} (µL/min/10 ⁶ cells)	_	7.7	For scenario two, the uptake $CL_{int,T}$ for E7766 measured at 0.3 µmol \underline{P} after 1 min incubation at 37 °C (Table 1) was assigned as input value for uptake $CL_{int,T}$ in SCHH, as garly time point and lower concentration can better represent the initial linear uptake phase.
REF _{SCHH}	_	1	The REF _{SCHH} is assumed to be one based on literature reported data shown that OATP1B1 and OATP1B3 expression levels are comparable between SCHH and primary hepatocyte if from the same lot (Kimoto et al., 2012)
Efflux $CL_{int,T}$ (µL/min/10 ⁶ cells)	2.1	2.1	For both scenarios one and two, SCHH efflux $CL_{int,T}$ for E7766 measured at 0.3 µmol/L after 20 min incubation at 37 °C (Table 1) was used as input value for Efflux $CL_{int,T}$.

B/P, blood-to-plasma partition ratio; f_u , unbound drug fraction in plasma; V_{ss} , distribution volume at steady state; K_p , tissue-to-plasma partition coefficients ; CL_{renal} , renal excretory clearance; CL_{PD} , passive diffusion clearance ; fuIW, unbound drug fraction in intracellular water; fuEW, unbound drug fraction in extracellular water; f_{uinc} , unbound drug fraction in in-vitro incubation system; K_m , Michaelis-Menten constant; J_{max} , in vitro maximum rate of transporter mediate uptake or efflux; REF, relative

expression factor; Uptake $CL_{int,T}$, intrinsic uptake clearance obtained from SCHH assay; Efflux $CL_{int,T}$, intrinsic biliary efflux clearance betained from SCHH assay. For scenario one, hepatic uptake clearance was assigned from the transporter kinetics measured in HEK 293 cells and for scenario two, measured in from SCHH was assigned to OATP1B3.

ded from dmd.aspetjournals.org at ASPET Journals on April 18, 2024

Table 5

Summary and comparison of simulated PK and DDI parameters of E7766 from PBPK models using two scenarios. Simcyp default compound for rifampicin was used for simulations. For scenario one, hepatic uptake clearance was assigned from the transporter kinetics measured in HEK 293 cells and for scenario two, intrinsic active uptake clearance measured in from SCHH was assigned to OATP1B3.

PKPD profile parameters of E7766	Scenario one		Scenario two	
	(-) Rifampicin	(+) Rifampicin	(-) Rifampicin	(+) Rifampicin
AUC _{total} (nmol·h/L)	47.38	131.06	67.26	174.07
AUC _{total} ratio	2.77		2.59	
$C_{\max, \text{tot}} (\text{nmol/L})$	474.01	479.92	476.24	480.12
$C_{\max, tot}$ ratio	1.01		1.01	
CL _{tot,p} (L/h)	29.62	11.88	21.55	8.66
CL _{tot,p} ratio	0.40		0.40	
Liver intracellular AUC _{free} (nmol·h/L)	76.19	69.06	71.35	61.28
Liver intracellular AUC _{free} ratio	0.91		0.86	

 AUC_{total} , area under total plasma concentration-time curve; AUC_{total} ratio, ratio of AUC_{total} in the presence and absence of the inhibitor; $C_{max,tot}$ maximum total plasma concentration; $C_{max,tot}$ ratio, ratio of $C_{max,tot}$ in the presence and absence of the inhibitor; $CL_{tot,p}$, total plasma clearance; $CL_{tot,p}$ ratio, ratio of CL_{tot} in the presence and absence of the inhibitor; Liver intracellular AUC_{free} , area under free intra-hepatocellular concentration-time curve; Liver intracellular AUC_{free} ratio, ratio of area under free intra-hepatocellular concentration-time curve in the presence and absence of the inhibitor.

Figures




Figure 1




Figure 2




Figure 3




Figure 4






Figure 5




· 2NH₃



3A


OATP1B1-specific Uptake of E7766




3B

OATP1B3-specific Uptake of E7766

Uptake velocity of E7766 (pmol/min/mg protein)



4A



4B

